Equity Overview
Price & Market Data
Price: $1.14
Daily Change: +$0.06 / 5.26%
Range: $1.04 - $1.17
Market Cap: $46,836,556
Volume: 8,283
Performance Metrics
1 Week: 12.87%
1 Month: -26.45%
3 Months: -25.97%
6 Months: -38.06%
1 Year: -56.15%
YTD: -32.14%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.